AUTHORS
Jill Johnsen, MD, G Shellye Horowitz, MS2, Danielle N Drury-Stewart, PhD3, Ziva Mann4, Bryan Comstock5, Kerry Lannert, MT(ASCP)6, Amber Keyser7, David Branch, MD8, Jean M. Connors, MD9, Shannon L. Meeks, MD10, Grier Page, Ph.D.11
AFFILIATIONS
1 University of Washington, Seattle, Washington, United States
2 University of Washington, Seattle, Washington, United States
3 University of Washington, Seattle, Washington, United States
4 Hemophilia A Research Program, Seattle, Washington, United States
5 University of Washington, Seattle, Washington, United States
6 University of Washington, Seattle, Washington, United States
7 University of Washington, Seattle, Washington, United States
8 University of Utah, Salt Lake City, United States
9 Dana Farber Cancer Institute, Boston, Massachusetts, United States
10 Emory University, Atlanta, Georgia, United States
11 RTI International, Atlanta, Georgia, United States
ABSTRACT
Introduction
Hemophilia A is an X-linked bleeding disorder caused by factor VIII (FVIII) deficiency. Knowledge gaps in hemophilia include predictors of postpartum hemorrhage in genotype-positive mothers (often called carriers) and understanding early mechanisms of inhibitor development. The Hemophilia A Research Program (HARP, NCT07414511) seeks to address these unmet needs through a longitudinal observational intergenerational cohort study of mothers and babies. HARP will follow 50 mother-baby pairs where the baby has severe hemophilia A beginning in pregnancy and through at least two years old. HARP collects data and samples, performs research, and creates a repository.
HARP was initially envisioned as a conventional multi-center study with a consortium of clinics leveraging the U.S. Hemophilia Treatment Center (HTC) network. However, as HARP formed in 2022-2023, it became clear that this design would be unlikely to meet HARP goals. Severe hemophilia A is rare, with ~150-200 babies born each year in the U.S. Mothers are therefore also rare and only eligible when pregnant. Furthermore, we conclude from CDC data that most genotype-positive females are not seen in HTCs. HTC providers are often unaware of pregnancies until right before birth or after the baby is born. Input of hematologists, OBs, genetic counselors, and community led us to conclude that care of pregnant mothers is heterogeneous and often fragmented. Mothers and babies also usually receive care across multiple institutions, casting doubt on the feasibility of a multi-site study structure.
To address these concerns, HARP revisited the protocol with multidisciplinary and community input and pivoted to an innovative fully decentralized adaptive study design.
Methods
A decentralized clinical study is a study where study-related activities occur at locations other than traditional study sites (e.g. local health care facilities, participant homes). An adaptive study prospectively modifies the study design based upon interim data. We have adopted new procedures across nearly all HARP components. Significant emphasis is placed on remote enrollment and retention. We obtain all data remotely including surveys and diaries, records, and safety data. Tools include phone, text, email, FAX, videoconference, REDCap surveys, and mail. Samples (blood, cord blood, placenta, stool) are collected locally and shipped to the Central Lab. F8 genotyping and inhibitor tests are done in CLIA labs. All procedures are IRB approved.
Results
The nature of recruitment is evolving. 3 of 4 mothers in the pilot were referred by providers. Later mothers were often identified through social media or word of mouth. At the time of this abstract, HARP has enrolled 15 pregnant mothers with 5 babies born on study, 3 with severe hemophilia A. The study has been conducted in 9 states across a variety of settings and 100% retention, including following participants as they moved.
Sample coordination requires significant effort. Local regulations need to be addressed early. All locations agreed that HARP sample collection does not constitute engagement in research. Participants, study team, and local partners are key in communications on study supplies, who collects samples, and timely transport, processing, storage, and shipping. Unexpected challenges commonly encountered include lack of phlebotomists, centrifuges, ultracold freezers, and after-hours staff. HARP has successfully navigated these challenges to obtain maternal, delivery, postpartum, neonatal, and child samples for each pair so far.
Completion of surveys by participants on their own time has been a critical point of flexibility. Timely access to medical records still poses challenges. Reporting by participants and providers has been accurate and reliable. Safety procedures use these sources to ensure timely reporting.
Discussion
HARP has created a new fully decentralized adaptive study design for mothers and their babies with severe hemophilia A to overcome the challenges of conventional studies. HARP is seeing early successes in enrollment, including mothers with no connection to HTCs or academic centers. A culture where participants are active partners in their own research has many positives including study improvements. Involvement of community and multidisciplinary experts is critical. In the past, studies in bleeding disorders have struggled to enroll. We hope HARP provides a new path for research in hemophilia and other rare disorders.
DISCLOSURES
Jill Johnsen, MD: Octapharma - Honoraria; MTEC - Research Funding; Sanofi - Research Funding; Hemophilia of Georgia - Research Funding; Octapharma - Research Funding; NHLBI - Research Funding; Washington Center for Bleeding Disorders - Research Funding